Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 78

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 78
---
 50% of our total voting power;

the sale or other disposition of all or substantially all of our assets;

our merger or consolidation after which our voting securities represent 50% or less of the total voting power of the surviving or acquiring entity; or

a majority of our Board being replaced, over a 12-month period, by persons whose appointment or election is not endorsed by a majority of our Board.

Changes in Capitalization.In the event of certain changes in our capital structure, such as a stock split, reverse stock split or dividend paid in common stock, the Administrator may determine, in its sole discretion as it deems appropriate, that adjustments will be made to:

the maximum number and kind of shares available for issuance under the 2025 Plan, including the maximum number and kind of shares that may be issued upon the exercise of ISOs;

the number and kind of shares covered by, and exercise price, base price or purchase price, if any, applicable to each outstanding stock award; and

the maximum number of shares and maximum cash award that may be granted to a participant in a calendar year.

The Administrator may also make other equitable substitutions or adjustments in its discretion.

<div align='center'>56</div>

New Plan Benefits. Future benefits under the 2025 Plan cannot be determined at this time because the grants are at the discretion of the Administrator and because their value may be dependent upon the satisfaction of vesting conditions and the future price of our common stock. No grants under the 2025 Plan have at this time been awarded or promised to any directors, employees or other eligible participants. However, if adopted by our stockholders, we do not expect our equity grant practices to differ in any material respect from our practices under the 2015 Plan, which are described above, including in “Executive Compensation” and “Why You Should Vote to Approve the 2025 Plan – Our Burn Rate Has Been Consistently Reasonable.” In addition, as described under “Director Compensation–Equity Awards” above, under our non-employee director compensation policy, each non-employee director nominee who will continue to serve as a member of the Board following the 2025 Annual Meeting will receive an equity grant with an aggregate value of $275,000, of which 75% will be granted in the form of NSOs and 25% will be granted in the form of RSUs. For 2025, we intend to grant these awards under the 2015 Plan. For information regarding securities authorized under current equity